Salesforce R&D increased by 13.0% to $1.62B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 44.7%, from $1.12B to $1.62B. Over 4 years (FY 2022 to FY 2026), R&D shows an upward trend with a 12.7% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $951.00M | $1.02B | $1.20B | $538.00M | $1.32B | $1.33B | $1.28B | $1.42B | $1.21B | $1.22B | $1.20B | $833.00M | $1.37B | $1.35B | $1.36B | $1.12B | $1.46B | $1.48B | $1.43B | $1.62B |
| QoQ Change | — | +7.3% | +17.9% | -55.3% | +145.0% | +0.8% | -3.7% | +11.3% | -15.2% | +1.1% | -1.3% | -30.8% | +64.2% | -1.4% | +0.5% | -17.5% | +30.5% | +1.4% | -3.2% | +13.0% |
| YoY Change | — | — | — | — | +38.6% | +30.3% | +6.4% | +164.7% | -8.4% | -8.2% | -5.9% | -41.5% | +13.3% | +10.6% | +12.6% | +34.3% | +6.7% | +9.8% | +5.7% | +44.7% |